Plain-English translation of NCT05664789 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a 12-week study testing whether N-acetylcysteine, a nutritional supplement, can help reduce repetitive and restricted behaviors in children with autism spectrum disorder. Half of the children will receive the active medication, and half will receive a placebo (an inactive pill that looks identical). The study will help researchers understand how this treatment works and whether it truly helps.
Some children with autism experience repetitive behaviors or routines that can interfere with daily life. Small early studies have suggested that this medication might help reduce these behaviors, but larger, more rigorous testing is needed to confirm whether it really works and to understand why.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic for a baseline visit, where researchers will confirm your diagnosis and measure your repetitive behaviors. You'll then take either the active medication or placebo by mouth once daily for 12 weeks. Some families who live close to the research site may also be asked to have an optional brain scan (MRI or EEG) to help researchers understand how the treatment works. You'll return for follow-up visits to check how you're doing and measure any changes in your behaviors.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States